About
Novo Nordisk's Rybelsus is in trials for its effects on cognitive decline, with results due December 3. It may offer a safer option compared to current injectable Alzheimer's treatments.1Analysts suggest concerns about Novo Nordisk's impact on the Danish economy may be exaggerated, as recent growth figures indicate a more stable outlook amid rising competition in weight-loss drugs.2Wellgistics Health is teaming up with Tollo Health to create products that address major side effects linked to GLP-1 drugs, including those from Novo Nordisk.3
AstraZeneca's Alexion unit gained FDA approval for Koselugo, now treating adults with neurofibromatosis type 1 and inoperable plexiform neurofibromas, boosting its market presence.123AstraZeneca's stock rose by 1% following the approval of its drug aimed at controlling the growth of non-cancerous tumors in the U.S., with an additional 0.4% increase noted in subsequent trading.4
Abbott Laboratories has agreed to acquire Exact Sciences Corp. for $21 billion, paying shareholders $105 per share. Exact Sciences, known for its cancer screening tests like Cologuard, expects to generate about $3 billion in revenue this year. This acquisition is part of a broader trend of pharmaceutical companies investing heavily in cancer screening development.
Health-care companies fell slightly amid deal activity. Exact Sciences surged after Abbott Laboratories agreed to acquire it for $21 billion. Moderna aims to stop losing money by 2028, despite taking a $1.5 billion loan. A CDC webpage now suggests vaccines might cause autism, reflecting changes under Health and Human Services Secretary Robert F. Kennedy.
TherapeuticsMD Inc. (TXMD) stock surged 16.36% to $1.92 on Thursday, outperforming competitors despite a poor trading session for the market. The NASDAQ fell 2.15% and the Dow Jones dropped 0.84%. This marks the third consecutive day of gains for TXMD, which closed 21.31% below its 52-week high. Trading volume exceeded its 50-day average. AbbVie Inc. (ABBV) fell 1.49%.
